AstraZeneca Results Presentation Deck
BioPharmaceuticals: R&D pipeline highlights
Four NMEs approved in 2021: Saphnelo, Tezspire, Evusheld and Vaxzevria
Evusheld
Only long-acting antibody combination
shown to prevent and treat COVID-19
• Authorised in eight countries,
including US EUA
Retains neutralising activity
against Omicron¹
US agreements for 1.2m doses
Agreements include
US Gov development
funding
EVUSHELD
ATTENTION HEALEY
Vaxzevria
Clinical and real-world evidence
supports use as booster
• 2.5bn doses supplied in 2021²
Boosts immune response
against Omicron³
• Retains neutralising activity
after two-doses4
• Vaxzevria and AZD2816-
generated similar immune
response to
variants of
concern5
Vaxzevria
5 ml
suspension for injection
COVID-19 Vaccine (ChAdOx1-5 recombinant)
Intramuscular use
10 multidose vials
(10 doses per vial-0.5 ml per dose)
108. Comme Bang super - 179 sin bas quase)
eplontersen
ATTR
Collaboration with lonis Pharmaceuticals
• ATTR: misfolded protein and
accumulation as amyloid fibrils
ATTR-CM (cardiomyopathy)
hATTR-PN (polyneuropathy,
hereditary)
Phase III trials:
CARDIO-TTRansform (data 2023+)
NEURO-TTRansform (data H2 2022)
26 1. Nature: doi.org/10.1038/s41586-021-04386-2 2. Includes doses shipped by sub-licensees. AstraZeneca invoiced supply is 963 million doses. 3. UK Health Security Agency: doi.org/10.1101/2021.12.14.21267615 4. The Lancet:
doi.org/10.1016/S0140-6736(22)00094-0 5. Interim results from the D7220C00001 clinical trial. ATTR = transthyretin amyloidosis.View entire presentation